Related references
Note: Only part of the references are listed.Pharmacokinetics and concentration-effect relationship of adalimumab in rheumatoid arthritis
David Ternant et al.
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY (2015)
A pharma perspective on the systems medicine and pharmacology of inflammation
Julio Lahoz-Beneytez et al.
MATHEMATICAL BIOSCIENCES (2015)
Development of a Population PK Model of Tacrolimus for Adaptive Dosage Control in Stable Kidney Transplant Patients
Franc Andreu et al.
THERAPEUTIC DRUG MONITORING (2015)
Key findings towards optimising adalimumab treatment: the concentration-effect curve
Mieke F. Pouw et al.
ANNALS OF THE RHEUMATIC DISEASES (2015)
The Comparative Safety of Tumor Necrosis Factor Inhibitors in Rheumatoid Arthritis: A Meta-analysis Update of 44 Trials
Tzeyu L. Michaud et al.
AMERICAN JOURNAL OF MEDICINE (2014)
Towards an individualised target concentration of adalimumab in rheumatoid arthritis
Emilie Ducourau et al.
ANNALS OF THE RHEUMATIC DISEASES (2014)
Pegylation of Biological Molecules and Potential Benefits: Pharmacological Properties of Certolizumab Pegol
Gianfranco Pasut
BIODRUGS (2014)
Relationship between inflammation and infliximab pharmacokinetics in rheumatoid arthritis
David Ternant et al.
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY (2014)
Therapeutic drug monitoring of once daily aminoglycoside dosing: comparison of two methods and investigation of the optimal blood sampling strategy
Lana Nezic et al.
EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY (2014)
Modeling approach to investigate the effect of neonatal Fc receptor binding affinity and anti-therapeutic antibody on the pharmacokinetic of humanized monoclonal anti-tumor necrosis factor-α IgG antibody in cynomolgus monkey
Chee M. Ng et al.
EUROPEAN JOURNAL OF PHARMACEUTICAL SCIENCES (2014)
The temporal evolution of antidrug antibodies in patients with inflammatory bowel disease treated with infliximab
Bella Ungar et al.
GUT (2014)
Mechanism-Based Approach Using a Biomarker Response to Evaluate Tocilizumab Subcutaneous Injection in Patients With Rheumatoid Arthritis With an Inadequate Response to Synthetic DMARDs (MATSURI Study)
Shuji Ohta et al.
JOURNAL OF CLINICAL PHARMACOLOGY (2014)
Monoclonal antibody disposition: a simplified PBPK model and its implications for the derivation and interpretation of classical compartment models
Ludivine Fronton et al.
JOURNAL OF PHARMACOKINETICS AND PHARMACODYNAMICS (2014)
Biologic therapies and pregnancy: the story so far
Kimme L. Hyrich et al.
RHEUMATOLOGY (2014)
The role of DMARDs in reducing the immunogenicity of TNF inhibitors in chronic inflammatory diseases
Meghna Jani et al.
RHEUMATOLOGY (2014)
Vancomycin Monitoring in Children Using Bayesian Estimation
Jennifer Le et al.
THERAPEUTIC DRUG MONITORING (2014)
Low- Versus High-Dose Rituximab for Rheumatoid Arthritis: A Systematic Review and Meta-Analysis
Markus Bredemeier et al.
ARTHRITIS CARE & RESEARCH (2014)
Basic Concepts in Population Modeling, Simulation, and Model-Based Drug Development: Part 3-Introduction to Pharmacodynamic Modeling Methods
R. N. Upton et al.
CPT-PHARMACOMETRICS & SYSTEMS PHARMACOLOGY (2014)
The Utility of Modeling and Simulation Approaches to Evaluate Immunogenicity Effect on the Therapeutic Protein Pharmacokinetics
Juan Jose Perez Ruixo et al.
AAPS JOURNAL (2013)
Safety of Anti-TNF Agents During Pregnancy and Breastfeeding in Women With Inflammatory Bowel Disease
Javier P. Gisbert et al.
AMERICAN JOURNAL OF GASTROENTEROLOGY (2013)
The immunogenicity of anti-TNF therapy in immune-mediated inflammatory diseases: a systematic review of the literature with a meta-analysis
Sandra Garces et al.
ANNALS OF THE RHEUMATIC DISEASES (2013)
Long-term measurement of anti-adalimumab using pH-shift-anti-idiotype antigen binding test shows predictive value and transient antibody formation
Pauline A. van Schouwenburg et al.
ANNALS OF THE RHEUMATIC DISEASES (2013)
Rituximab-Induced T Cell Depletion in Patients With Rheumatoid Arthritis Association With Clinical Response
J. Melet et al.
ARTHRITIS AND RHEUMATISM (2013)
The combined use of disease activity and infliximab serum trough concentrations for early prediction of (non-)response to infliximab in rheumatoid arthritis
Bart J. F. van den Bemt et al.
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY (2013)
A systems biology approach to suppress TNF-induced proinflammatory gene expressions
Kentaro Hayashi et al.
CELL COMMUNICATION AND SIGNALING (2013)
Pharmacokinetics and Safety of Golimumab in Healthy Chinese Subjects Following a Single Subcutaneous Administration in a Randomized Phase I Trial
Yanli Zhuang et al.
CLINICAL DRUG INVESTIGATION (2013)
Placental Transfer of Anti-Tumor Necrosis Factor Agents in Pregnant Patients With Inflammatory Bowel Disease
Uma Mahadevan et al.
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY (2013)
Pharmacokinetics, Pharmacodynamics and Physiologically-Based Pharmacokinetic Modelling of Monoclonal Antibodies
Miroslav Dostalek et al.
CLINICAL PHARMACOKINETICS (2013)
Pharmacokinetics and pharmacodynamics of single subcutaneous doses of tocilizumab administered with or without rHuPH20
Peter N. Morcos et al.
INTERNATIONAL JOURNAL OF CLINICAL PHARMACOLOGY AND THERAPEUTICS (2013)
Theoretical analysis of efficacy of biological agent for rheumatoid arthritis based on target molecular binding occupancy
Kanae Tani et al.
RHEUMATOLOGY INTERNATIONAL (2013)
Basic Concepts in Population Modeling, Simulation, and Model-Based Drug Development-Part 2: Introduction to Pharmacokinetic Modeling Methods
Dr Mould et al.
CPT-PHARMACOMETRICS & SYSTEMS PHARMACOLOGY (2013)
Influence of methotrexate on infliximab pharmacokinetics and pharmacodynamics in ankylosing spondylitis
David Ternant et al.
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY (2012)
Concordance of preclinical and clinical pharmacology and toxicology of monoclonal antibodies and fusion proteins: soluble targets
Pauline L. Martin et al.
BRITISH JOURNAL OF PHARMACOLOGY (2012)
Therapeutic Drug Monitoring of Imatinib Bayesian and Alternative Methods to Predict Trough Levels
Verena Gotta et al.
CLINICAL PHARMACOKINETICS (2012)
Local versus Systemic Anti-Tumour Necrosis Factor-α Effects of Adalimumab in Rheumatoid Arthritis Pharmacokinetic Modelling Analysis of Interaction between a Soluble Target and a Drug
David Stepensky
CLINICAL PHARMACOKINETICS (2012)
Anti-TNF Monoclonal Antibodies in Inflammatory Bowel Disease: Pharmacokinetics-Based Dosing Paradigms
Ingrid Ordas et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2012)
Lessons from mathematically modeling the NF-κB pathway
Soumen Basak et al.
IMMUNOLOGICAL REVIEWS (2012)
Risk of Malignancies in Patients With Rheumatoid Arthritis Treated With Biologic Therapy A Meta-analysis
Maria A. Lopez-Olivo et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2012)
Development of a new immunoassay for the accurate determination of anti-infliximab antibodies in inflammatory bowel disease
Hirotsugu Imaeda et al.
JOURNAL OF GASTROENTEROLOGY (2012)
Linking interleukin-6 receptor blockade with tocilizumab and its hematological effects using a modeling approach
Leonid Gibiansky et al.
JOURNAL OF PHARMACOKINETICS AND PHARMACODYNAMICS (2012)
Lifespan based indirect response models
Wojciech Krzyzanski et al.
JOURNAL OF PHARMACOKINETICS AND PHARMACODYNAMICS (2012)
Theory-based analysis of anti-inflammatory effect of infliximab on Crohn's disease and rheumatoid arthritis
Koji Kimura et al.
RHEUMATOLOGY INTERNATIONAL (2012)
Rheumatoid Arthritis Disease Activity Measures: American College of Rheumatology Recommendations for Use in Clinical Practice
Jaclyn Anderson et al.
ARTHRITIS CARE & RESEARCH (2012)
Multi-Scale In Vivo Systems Analysis Reveals the Influence of Immune Cells on TNF-α-Induced Apoptosis in the Intestinal Epithelium
Ken S. Lau et al.
PLOS BIOLOGY (2012)
American College of Rheumatology/European League Against Rheumatism Provisional Definition of Remission in Rheumatoid Arthritis for Clinical Trials
David T. Felson et al.
ARTHRITIS AND RHEUMATISM (2011)
Anti-infliximab antibodies are already detectable in most patients with rheumatoid arthritis halfway through an infusioncycle: an open-label pharmacokinetic cohort study
Bart JF van den Bemt et al.
BMC MUSCULOSKELETAL DISORDERS (2011)
Interpreting population pharmacokinetic-pharmacodynamic analyses - a clinical viewpoint
Stephen B. Duffull et al.
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY (2011)
Pharmacokinetic Properties of Infliximab in Children and Adults with Crohn's Disease: A Retrospective Analysis of Data from 2 Phase III Clinical Trials
Adedigbo A. Fasanmade et al.
CLINICAL THERAPEUTICS (2011)
Population pharmacokinetics of golimumab in patients with ankylosing spondylitis: impact of body weight and immunogenicity
Z.H. Xu et al.
INTERNATIONAL JOURNAL OF CLINICAL PHARMACOLOGY AND THERAPEUTICS (2011)
Population Approach for Exposure-Response Modeling of Golimumab in Patients With Rheumatoid Arthritis
Chuanpu Hu et al.
JOURNAL OF CLINICAL PHARMACOLOGY (2011)
Risk of adverse events including serious infections in rheumatoid arthritis patients treated with tocilizumab: a systematic literature review and meta-analysis of randomized controlled trials
Laura Campbell et al.
RHEUMATOLOGY (2011)
Evaluating the efficacy of sequential biologic therapies for rheumatoid arthritis patients with an inadequate response to tumor necrosis factor-alpha inhibitors
Regina Rendas-Baum et al.
ARTHRITIS RESEARCH & THERAPY (2011)
Antibodies toward infliximab are associated with low infliximab concentration at treatment initiation and poor infliximab maintenance in rheumatic diseases
Emilie Ducourau et al.
ARTHRITIS RESEARCH & THERAPY (2011)
Biodistribution Mechanisms of Therapeutic Monoclonal Antibodies in Health and Disease
Mohammad Tabrizi et al.
AAPS JOURNAL (2010)
Clinical response, pharmacokinetics, development of human anti-chimaeric antibodies, and synovial tissue response to rituximab treatment in patients with rheumatoid arthritis
R. M. Thurlings et al.
ANNALS OF THE RHEUMATIC DISEASES (2010)
Population Pharmacokinetics of Therapeutic Monoclonal Antibodies
Nathanael L. Dirks et al.
CLINICAL PHARMACOKINETICS (2010)
Subset Analysis of Patients Experiencing Clinical Events of a Potentially Immunogenic Nature in the Pivotal Clinical Trials of Tocilizumab for Rheumatoid Arthritis: Evaluation of an Antidrug Antibody ELISA Using Clinical Adverse Event-Driven Immunogenicity Testing
Kay Stubenrauch et al.
CLINICAL THERAPEUTICS (2010)
Pharmacology of TNF blockade in rheumatoid arthritis and other chronic inflammatory diseases
Peter C. Taylor
CURRENT OPINION IN PHARMACOLOGY (2010)
Population Pharmacokinetic Analysis of Tocilizumab in Patients With Rheumatoid Arthritis
Nicolas Frey et al.
JOURNAL OF CLINICAL PHARMACOLOGY (2010)
A novel method for the detection of antibodies to adalimumab in the presence of drug reveals hidden immunogenicity in rheumatoid arthritis patients
Pauline A. van Schouwenburg et al.
JOURNAL OF IMMUNOLOGICAL METHODS (2010)
The effect of immunomodulators on the immunogenicity of TNF-blocking therapeutic monoclonal antibodies: a review
Charlotte Louise Maria Krieckaert et al.
ARTHRITIS RESEARCH & THERAPY (2010)
Golimumab for rheumatoid arthritis
Jasvinder A. Singh et al.
COCHRANE DATABASE OF SYSTEMATIC REVIEWS (2010)
Formation of antibodies against infliximab and adalimumab strongly correlates with functional drug levels and clinical responses in rheumatoid arthritis
T. R. D. J. Radstake et al.
ANNALS OF THE RHEUMATIC DISEASES (2009)
Risk of serious infections during rituximab, abatacept and anakinra treatments for rheumatoid arthritis: meta-analyses of randomised placebo-controlled trials
C. Salliot et al.
ANNALS OF THE RHEUMATIC DISEASES (2009)
Golimumab, a human antibody to tumour necrosis factor α given by monthly subcutaneous injections, in active rheumatoid arthritis despite methotrexate therapy: the GO-FORWARD Study
E. C. Keystone et al.
ANNALS OF THE RHEUMATIC DISEASES (2009)
A Pharmacodynamic Markov Mixed-Effects Model for Determining the Effect of Exposure to Certolizumab Pegol on the ACR20 Score in Patients With Rheumatoid Arthritis
B. D. Lacroix et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2009)
Population pharmacokinetic analysis of infliximab in patients with ulcerative colitis
Adedigbo A. Fasanmade et al.
EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY (2009)
Target-mediated drug disposition model: approximations, identifiability of model parameters and applications to the population pharmacokinetic-pharmacodynamic modeling of biologics
Leonid Gibiansky et al.
EXPERT OPINION ON DRUG METABOLISM & TOXICOLOGY (2009)
Influence of Trough Serum Levels and Immunogenicity on Long-term Outcome of Adalimumab Therapy in Crohn's Disease
Konstantinos Karmiris et al.
GASTROENTEROLOGY (2009)
TUMOR NECROSIS FACTOR-ALPHA ANTAGONISTS: DIFFERENTIAL CLINICAL EFFECTS BY DIFFERENT BIOTECHNOLOGICAL MOLECULES
F. Licastro et al.
INTERNATIONAL JOURNAL OF IMMUNOPATHOLOGY AND PHARMACOLOGY (2009)
Infliximab concentration monitoring improves the control of disease activity in rheumatoid arthritis
Denis Mulleman et al.
ARTHRITIS RESEARCH & THERAPY (2009)
Monoclonal Antibody Pharmacokinetics and Pharmacodynamics
W. Wang et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2008)
Population pharmacokinetics of infliximab in patients with ankylosing spondylitis
Zhenhua Xu et al.
JOURNAL OF CLINICAL PHARMACOLOGY (2008)
Approximations of the target-mediated drug disposition model and identifiability of model parameters
Leonid Gibiansky et al.
JOURNAL OF PHARMACOKINETICS AND PHARMACODYNAMICS (2008)
Tumor necrosis factor antagonist mechanisms of action: A comprehensive review
Daniel Tracey et al.
PHARMACOLOGY & THERAPEUTICS (2008)
Structure-function relationships of the variable domains of monoclonal antibodies approved for cancer treatment
Charlotte Magdelaine-Beuzelin et al.
CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY (2007)
Double-blinded infliximab dose escalation in patients with rheumatoid arthritis
Mahboob U. Rahman et al.
ANNALS OF THE RHEUMATIC DISEASES (2007)
Clinical response to adalimumab: relationship to anti-adalimumab antibodies and serum adalimumab concentrations in rheumatoid arthritis
Geertje M. Bartelds et al.
ANNALS OF THE RHEUMATIC DISEASES (2007)
A mechanism-based binding model for the population pharmacokinetics and pharmacodynamics of omalizumab
Naoto Hayashi et al.
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY (2007)
Pharmacokinetics and safety of golimumab, a fully human anti-TNF-α monoclonal antibody, in subjects with rheumatoid arthritis
Honghui Zhou et al.
JOURNAL OF CLINICAL PHARMACOLOGY (2007)
Clinical pharmacokinetics and pharmacodynamics of mycophenolate in solid organ transplant recipients
Christine E. Staatz et al.
CLINICAL PHARMACOKINETICS (2007)
Theory based analysis of anti-inflammatory effect of infliximab on Crohn's disease
Yoko Furuya et al.
DRUG METABOLISM AND PHARMACOKINETICS (2007)
Relevance, advantages and limitations of animal models used in the development of monoclonal antibodies for cancer treatment
Severine Loisel et al.
CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY (2007)
Individualized monitoring of drug bioavailability and immunogenicity in rheumatoid arthritis patients treated with the tumor necrosis factor α inhibitor infliximab
Klaus Bendtzen et al.
ARTHRITIS AND RHEUMATISM (2006)
Anti-TNF antibody therapy in rheumatoid arthritis and the risk of serious infections and malignancies - Systematic review and meta-analysis of rare harmful effects in randomized controlled trials
T Bongartz et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2006)
Human anti-tumor necrosis factor monoclonal antibody (adalimumab) in Crohn's disease: the CLASSIC-I trial
SB Hanauer et al.
GASTROENTEROLOGY (2006)
Elimination mechanisms of therapeutic monoclonal antibodies
MA Tabrizi et al.
DRUG DISCOVERY TODAY (2006)
Pharmacokinetics/pharmacodynamics of nondepleting anti-CD4 monoclonal antibody (TRX1) in healthy human volunteers
CM Ng et al.
PHARMACEUTICAL RESEARCH (2006)
Dose intensification with infliximab in patients with rheumatoid arthritis
A Berger et al.
ANNALS OF PHARMACOTHERAPY (2005)
Population pharmacokinetics of rituximab (anti-CD20 monoclonal antibody) in rheumatoid arthritis patients during a phase II clinical trial
CM Ng et al.
JOURNAL OF CLINICAL PHARMACOLOGY (2005)
Relationship between serum trough infliximab levels, pretreatment C reactive protein levels, and clinical response to infliximab treatment in patients with rheumatoid arthritis
GJ Wolbink et al.
ANNALS OF THE RHEUMATIC DISEASES (2005)
Pharmacokinetics and concentration-effect relationships of therapeutic monoclonal antibodies and fusion proteins
D Ternant et al.
EXPERT OPINION ON BIOLOGICAL THERAPY (2005)
Clinical experience with inhibition of interleukin-6
E Choy
RHEUMATIC DISEASE CLINICS OF NORTH AMERICA (2004)
In vitro internalization, intracellular transport, and clearance of an anti-CD11a antibody (Raptiva) by human T-cells
GP Coffey et al.
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS (2004)
Efficacy of B-cell-targeted therapy with rituximab in patients with rheumatoid arthritis
JCW Edwards et al.
NEW ENGLAND JOURNAL OF MEDICINE (2004)
Antibody pharmacokinetics and pharmacodynamics
ED Lobo et al.
JOURNAL OF PHARMACEUTICAL SCIENCES (2004)
Treatment of rheumatoid arthritis with humanized anti-interleukin-6 receptor antibody - A multicenter, double-blind, placebo-controlled trial
N Nishimoto et al.
ARTHRITIS AND RHEUMATISM (2004)
Drug therapy - New drugs for rheumatoid arthritis
NJ Olsen et al.
NEW ENGLAND JOURNAL OF MEDICINE (2004)
Efficacy, pharmacokinetic, and safety assessment of adalimumab, a fully human anti-tumor necrosis factor-alpha monoclonal antibody, in adults with rheumatoid arthritis receiving concomitant methotrexate: A pilot study
MH Weisman et al.
CLINICAL THERAPEUTICS (2003)
Influence of immunogenicity on the long-term efficacy of infliximab in Crohn's disease
F Baert et al.
NEW ENGLAND JOURNAL OF MEDICINE (2003)
The relationship of serum infliximab concentrations to clinical improvement in rheumatoid arthritis - Results from ATTRACT, a multicenter, randomized, double-blind, placebo-controlled trial
EWS Clair et al.
ARTHRITIS AND RHEUMATISM (2002)
General pharmacokinetic model for drugs exhibiting target-mediated drug disposition
DE Mager et al.
JOURNAL OF PHARMACOKINETICS AND PHARMACODYNAMICS (2001)
Share Paper
